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Purpose: A comparison of aortofemoral bypass grafting (AOFBG) and axiUofemoral 
bypass grafting (AXFBG) for occlusive disease performed by the same surgeons during a 
defined interval forms the basis for this report. 
Methods: Data regarding all patients who underwent AOFBG or AXFBG for lower- 
extremity ischemia caused by aortoiliac occlusive disease were prospectively entered into 
a computerized vascular registry. The decision to perform AOFBG rather than AXFBG 
was based on assessment of surgical risk and the surgeon's preference. This report describes 
results for surgical morbidity, mortality, patency, limb salvage, and patient survival for 
procedures performed from January 1988 through December 1993. 
Results: We performed 108 AXFBGs and 139 AOFBGs. AXFBG patients were older 
(mean age, 68 years compared with 58 years for AOFBG, p < 0.001), more often had 
heart disease (84% compared with 38%,p < 0.001), and more often underwent surgery 
for limb-salvage indications (80% compared with 42%, p < 0.001). No significant 
differences were found in operative mortality (AXFBG, 3.4%; AOFBG, < 1.0%,p = NS), 
but major postoperative complications occurred more frequently after AOFBG (AXFBG, 
9.2%; AOFBG, 19.4%; p < 0.05). Follow-up ranged from 1 to 83 months (mean, 27 
months). Five-year life-table primary patency, limb salvage, and survival rates were 74%, 
89%, and 45% for AXFBG and 80%, 79%, and 72% for AOFBG, respectively. Although 
the patient survival rate was statistically ower with AXFBG, primary patency and limb 
salvage rates did not differ when compared with AOFBG. 
Conclusion: When reserved for high-risk patients with limited life expectancy, the patency 
and limb salvage results of AXFBG are equivalent to those of AOFBG. (J Vase SURG 
1996;23:263-71.) 
Aortofemoral bypass grafting (AOFBG) is the 
standard surgical treatment for aortoiliac occlusive 
disease, partly because of a S-year patency rate that 
exceeds 80% in many reports. >6 With the nearly si- 
multaneous reports of Blaisdell and Hall r and Louw 8 
in 1963, axillofemoral bypass grafting (AXFBG) was 
introduced as an alternative technique for lower- 
extremity inflow revascularization. Widespread use 
From the Division of Vascular Surgery, Department of Surgery, 
Oregon Health Sciences University, Portland Veterans Affairs 
Hospital. 
Supported in part by NIH Grant RR-00334, General Clinical 
Research Centers Branch, National Center fo Research Re- 
sources. 
Presented atthe Forty-ninth Annual Meeting of the Society for 
Vascular Surgery, New Orleans, La., June 11-12, 1995. 
Reprint requests: Lloyd M. Taylor, Jr., MD, Division of Vascular 
Surgery, OP-11, 3181 S.W. Sam Jackson Park Road, Portland, 
OR 97201. 
24/6/69713 
of AXFBG for treatment of aortoiliac occlusive dis- 
ease was limited in the past because long-term pa- 
tency rates were inferior to those reported for 
AOFBG. 9-14 
Patency results achieved with AXFBG have im- 
proved recently, which is temporally related to the 
introduction of externally supported prostheses. Pri- 
mary patency rates of > 70% at 5 years have been 
reported by several investigators.l~-~8 These results of 
AXFBG are noteworthy for superiority over previous 
AXFBG series and for a striking similarity to patency 
results from AOFBG series. Although few studies 
have compared AXFBG and AOFBG, 13,19"22 none 
were prospective. No reports have been published 
about concurrent AXFBG and AOFBG procedures 
performed by the same surgeons at a single institu- 
non. A comparison of prospectively collected results 
of all AXFBG and AOFBG procedures performed for 
occlusive disease by the vascular surgery service at the 
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Oregon Health Sciences University during a single 
time period forms the basis for this report. 
METHODS 
Data about all patients who underwent AXFBG 
or AOFBG at the Oregon Health Sciences University 
Hospital and Portland Veterans Affairs Hospital 
from January 1, 1988, to December 31, 1993, for 
lower-extremity ischemia caused by aortoiliac occlu- 
sive disease were entered prospectively into a com- 
puterized vascular registry. Excluded from this study 
were procedures performed for abdominal aortic 
aneurysm, trauma, aortoenteric fistula, aortic graft 
infection, or any indication except ischemia caused by 
atherosclerotic occlusive disease. Repeat AXFBG 
performed to treat failure of an initial AXFBG were 
also excluded (n = 9) to preserve the independence 
of the observations compared (i.e., to avoid counting 
individual patient data twice). The results with 
respect to all parameters evaluated were not altered by 
this exclusion. 
Before surgery, patient demographic data and 
associated medical conditions were recorded. Non- 
invasive vascular laboratory evaluation of the lower 
extremities with methods previously described was 
obtained. 23 Complete arteriography of the aorta and 
lower extremities was performed before elective 
surgery. Patients who underwent AXFBG had non- 
invasive preoperative t sting to assess axillary artery 
inflow. Upper-extremity arteriography was per- 
formed in patients with abnormal study results, as 
previously described. 17
Choice of AOFBG or AXFBG for each patient 
was not randomized, but was made by each operating 
surgeon on the basis of an assessment ofsurgical risk. 
AXFBG was selected when AOFBG was relatively 
contraindicated byoperative technical factors uch as 
multiple previous abdominal or aortic surgeries, 
radiation, or stoma, or by systemic factors such as 
advanced age, severe cardiac or pulmonary disease, or 
other severe medical illness. No specific criteria were 
used for the choice of AXFBG or AOFBG; the 
decision was made on an individual basis for each 
patient by each attending surgeon. Concomitant 
infrainguinal bypass was performed in patients with 
multilevel disease in whom an inflow procedure alone 
would have been insufficient for complete revascu- 
larization, as we have previously described. 24
The operative technique for AXFBG has been 
described previously. 17,18,2s All grafts were con- 
structed of 8-ram externally supported polytetraflu- 
oroethylene. The axillofemoral component of the 
graft was tunnelled subcutaneously from the axilla in 
the midaxillary line, medial to the anterior superior 
iliac spine, to the ipsilateral femoral artery. Proximal 
anastomosis was performed in an end-to-side fashion 
to a longitudinal arteriotomy in the first portion of 
the axillary artery, followed by distal anastomosis to
the femoral artery for axillotmifemoral bypass or to 
the ipsilateral anastomotic "hood" of a previously 
placed femorofemoral bypass for axillobifemoral 
bypass. 
AOFBG was performed by retroperitoneal or 
transperitoneal exposure according to the preference 
of the operating surgeons. All AOFBGs were per- 
formed with woven Dacron grafts. Distal anasto- 
moses were to the common femoral, superficial 
femoral, or deep femoral arteries depending on the 
pattern of occlusive disease at the femoral level. 
Femoral endarterectomy and profundaplasty were 
performed when appropriate as previously de- 
scribed. 26 All operations were performed by one or 
more of the authors acting as teaching assistant to 
vascular surgery and general surgery residents. 
After surgery, patients were seen by one of the 
authors for follow-up visits every 3 months for the 
first year and every 6 months thereafter. Graft patency 
was assessed at each visit by clinical examination and 
by noninvasive vascular laboratory examination. Sus- 
pected graft occlusions were confirmed by arteriog- 
raphy. Long-term primary patency, secondary pa- 
tency, limb salvage, and survival rates were deter- 
mined with standard life-table analysis as defined by 
published reporting standards. 27Limb salvage was 
defined as rest pain, the presence of ischemic ulcer- 
ation with anlde-brachial index of _> 0.40, or both. 
For AXFBG, failure of the axillofemoral or femoro- 
femoral component or of both components was 
regarded as failure of the entire graft. For AOFBG, 
failure of either limb was regarded as failure of the 
graft. Patency rates were calculated on the basis of the 
number of grafts, limb salvage rates were calculated 
from the number of limbs at risk, and survival rates 
were calculated from the number of patients. Com- 
parisons among the groups were tested with X 2 
analysis for conditional variables and the log-rank test 
for life-table results. 
PATIENTS 
Demographics. During the study period, 108 
AXFBG were performed in 108 patients and 139 
AOFBG were performed in 139 patients. The age 
range for the entire study population was 35 years to 
90 years. Patients who underwent AXBFG tended to 
be older than patients who underwent AOFBG 
(mean age of 68.12 + 11.42 years compared with 
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Table I. Associated medical conditions in patients who underwent axillofemoral nd " 
aortofemoral bypass 
Condition Axillofemoral bypass (n = 108) Aortofemoral bypass (n = 139) p ~ 
Age >80years 10 (9%) 0 (0%) <0.001 
Tobacco use 93 (86%) 114 (82%) NS 
Heart disease 91 (84%) 52 (38%) <0.001 
Chronic pulmonary disease 14 (13%) 17 (12%) NS 
Diabetes mellitus 31 (29%) 27 (19%) NS 
Chronic renal failure 12 (11%) 3 (2%) <0.01 
Prior intraabdominal surgery 48 (44%) 42 (30%) <0.05 
Prior aortic surgery 17 (16%) 8 (6%) <0.05 
~X 2 analysis. 
Table II. Indication for axillofemoral nd aortofemoral bypass 
Indication Axillofemoral bypass (n = 108) dortofemoral bypass (n = 139) p ~ 
Claudication 22 (20%) 81 (58%) <0.001 
Rest pain 53 (49%) 44 (32%) <0.001 
Ischemic ulcer or gangrene 33 (31%) 14 (10%) <0.001 
~×2 analysis. 
58.71 +_ 10.21 years; p < 0.001 by t test compari- 
son of means). Seventy-two patients who underwent 
AXFBG (67%) and 107 patients who underwent 
AOFBG (77%) were male (p = NS). 
Clinical presentation. Associated medical con- 
ditions are summarized in Table I. Patients who 
underwent AXBFG were significantly more likely to 
have heart disease (p < 0.001), chronic renal failure 
(p < 0.01), and previous intraabdominal or aortic 
surgery (p < 0.05). Incidence of diabetes mellitus, 
chronic pulmonary disease, and tobacco use did not 
differ. 
Indications for surgery are shown in Table II. 
Limb salvage was the indication for surgery in 86 
patients with AXBFG (80%), as compared with 58 
patients with AOFBG (42%) (p < 0.001). Claud]- 
cation was a more frequent indication for AOFBG, 
representing 81procedures (58%) as compared with 
22 (20%) for AXFBG (p < 0.001). 
Types of surgical procedures. Of the 108 
AXFBGs, 99 were of an axillobifemoral configura- 
tion (92%) and 9 were axillounifemoral (8%). Of the 
139 AOFBGs, 76 were performed with a transperi- 
toneal approach (55 %) and 63 with a retroperitoneal 
approach (45%; p = NS). 
Superficial femoral artery occlusion occurred 
more frequently in patients who underwent AXFBG 
than in those in the AOFBG group, as demonstrated 
in Table III (p < 0.001). One or both superficial 
femoral arteries were occluded before 81 AXFBG 
(75%), as compared with 79 AOFBG procedures 
(57%) (p < 0.005). Concurrent infrainguinal by- 
pass was also performed more frequently with 
AXBFG (33 of 108, 31%) than with AOFBG (22 of 
139, i5%;p < 0.05). 
Perioperative morbidity and mortality rates. 
Four perioperative d aths occurred after AXBFG and 
one after AOFBG, which yields 30-day operative 
mortality rates of 3.4% and < 1.0%, respectively 
(p = NS). After AXBFG two patients died of 
myocardial infarction, one of cardiac arrhythmia, nd 
one of stroke; after AOFBG one patient died of 
stroke. 
Major postoperative complications occurred less 
frequently after AXFBG (9.2%) than after AOFBG 
(19.4%) (p < 0.05). Myocardial infarction, graft 
occlusion, and bleeding that required reoperation 
occurred with similar frequency for both procedures 
(data not shown). Pulmonary failure, acute renal 
failure, and stroke occurred more frequently in 
patients undergoing AOFBG. Ten wound complica- 
tions (including superficial infection, hematoma, or 
lymphocele) occurred after AXFBG (9.2%) and 18 
after AOFBG (12.4%) (to = NS). 
Patency. Follow-up ranged from i to 83 months 
(mean, 27 months). Mean follow-up for AXFBG was 
significantly shorter than for AOFBG (AXFBG, 18 
months; AOFBG, 28 months; p < 0.05), which 
reflects the shortened survival time of AXFBG 
patients, as described below. Seventeen AXBFGs 
(15.7%) became occluded, including six in the 
axillofemoral segment alone, five in the femorofemo- 
ral segment alone, and six in both segments. Primary 
patency was lost in 16 AOFBGs (11.5%) because of 
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Table III. Patency of superficial femoral artery and use of concominant infrainguinal bypass at the 
time of axillofemoral or aortofemoral bypass 
Axillofemoral bypass (n = 108) Aortofemoral bypass (n = 139) p* 
Superficial femoral artery patency 
None 66 (61%) 28 (20%) <0.001 
One 15 (14%) 51 (37%) <0.001 
Both 27 (25%) 60 (43%) <0.01 
Infrainguinal bypass 
Unilateral 27 (25%) 20 (14%) NS 
Bilateral 3 (3%) 2 (1%) NS 
Total number of limbst 33 (31%) 22 (15%) < 0.05 
*X 2 analysis. 
tRefers to the total number of concominant infrainguinal bypass procedures performed. 
Table IV. Life-table primary patency of axillofemoral bypass (n = 108) 
Period At  risk Occluded Withdrawn Interval patency Cumulative patency 
(too) (no.) (no.) (no.) rate rate S E 
0-1 108 i 7 0.99 0.99 0.01 
2-6 100 6 21 0.93 0.92 0.03 
7-12 73 2 11 0.97 0.9 0.03 
13-24 60 7 20 0.86 0.77 0.05 
25-36 33 1 17 0.96 0.74 0.07 
37-48 15 0 6 1 0.74 0.1 
49-60 9 0 8 1 0.74 0.13 
10 single-limb occlusions, 3 complete graft occlu- 
sions, repair of 2 distal graft pseudoaneurysms, and 
removal of 1 infected graft. Life-table primary 
patency rates at 5 years for AXFBG and AOFBG were 
74% and 80%, respectively (p = NS), as shown in 
Tables IV and V. Primary patency of both procedures 
was not significantly affected by the indication for 
surgery, the patency of the superficial femoral arter- 
ies, or the need for concomitant infrainguinal bypass 
(data not shown). For AOFBG, patency rates did not 
differ on the basis of surgical exposure, with 5-year 
primary patency rates of 83% for the transperitoneal 
approach and 77% for the retroperitoncal approach 
(p = NS). 
All graft occlusions were accompanied by recur- 
rent symptoms of lower-extremity schemia. Seven- 
teen secondary procedures were performed to treat 
AXBFG occlusions. Ten of these were placement of 
a new AXFBG or femorofemoral bypass, and seven 
were revisions with or without thrombectomy. 
Fifteen secondary procedures were performed to 
treat AOFBG occlusions: one graft replacement, 
eight thrombectomies or revisions, and six AXFBG 
or femorofemoral bypasses. The secondary patency 
rate at 5 years for AXFBG (81%) was significantly 
lower than that of AOFBG (92%) (p < 0.025; log 
rank test). This difference between secondary and 
primary patency rates reflects the authors' preference 
for, thrombectomy/revision t  treat AOFBG limb 
occlusion rather than repeat bypass grafting to treat 
AXFBG occlusion. 
Limb salvage. Eighty-six patients (114 limbs) 
underwent AXFBG and 58 patients (71 limbs) 
underwent AOFBG for limb-salvage indications. 
During follow-up, seven limbs were amputated from 
seven patients who had undergone AXFBG, and 
seven limbs were amputated from six patients after 
AOFBG. All amputations occurred after progression 
of inoperable infrainguinal disease, failure of infrain- 
guinal revascularization, or both. No amputations 
resulted irectly from failure of AXFBG or AOFBG 
alone. All patients who required amputation origi- 
nally underwent surgery for limb-salvage indications. 
No amputations were performed in patients who 
underwent surgery for claudication. After 5 years, 
life-table limb salvage rates were 89% for AXFBG 
and 78% for AOFBG (p = NS). 
Late mortality. Five-year survival rates by 
life-table analysis were 45% after AXBFG and 72% 
after AOFBG (p < 0.01) (Tables VI and VII). 
Including the immediate postoperative deaths, 28 
deaths occurred uring follow-up after AXBFG and 
25 occurred after AOFBG. The most frequent cause 
of death after AXBFG was cardiac disease (13 
patients, 46 %), followed by cancer (5 patients, 18 %), 
stroke (2 patients, 7%), and unknown causes (8 
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Table V. Life-table primary patency of aortofemoral bypass (n = 139) 
Period At  risk Occluded Withdrawn Interval patency Cumulative patency 
(too) (no.) (no.) (no.) rate rate SE 
0-1 139 2 5 0.99 0.99 0.01 
2-6 132 3 11 0.98 0.96 0.02 
7-12 118 3 14 0.97 0.94 0.02 
13-24 101 3 29 0.97 0,9 0.03 
25-36 69 3 23 0.95 0.86 0.04 
37-48 43 1 10 0.97 0.83 0.05 
49-60 32 1 19 0.96 0.8 0.06 
Table VI. Life-table survival for axillofemoral bypass (n = 108) 
Period At  risk Death Withdrawn Interval survival Cumulative survival 
(too) (no.) (no.) (no.) rate rate S E 
0-1 108 4 3 0.96 0.96 0.02 
2-6 101 5 I7 0.95 0.91 0.03 
7-12 79 4 10 0.95 0.86 0.04 
13-24 65 6 20 0.89 0.77 0.05 
25-36 39 8 17 0.74 0.57 0.06 
37-48 14 0 7 1 0.57 0.1 
49-60 7 1 4 0.8 0.45 0.13 
patients, 29%). After AOFBG, 9 deaths (36%) 
resulted from cardiac disease, 6 (24%) from cancer, 
1 (4%) from stroke, and 9 (36%) from unknown 
causes.  
DISCUSSION 
Patients with symptomatic aortoiliac occlusive 
disease sufficiently severe to warrant interventional 
treatment can be treated by percutaneous techniques, 
including balloon angioplasty and stenting, or by 
operative techniques. Although minimally invasive, 
percutaneous techniques are limited in application by 
a therapeutic paradox. The more extensive the disease 
and the more severe the patient's ymptoms, the less 
likely percutaneous therapy will be successful or even 
feasible. AOFBG and AXFBG can be performed in 
patients with the most severe occlusive disease. 
Although reported 5-year patency rates after AOFBG 
have consistently exceeded 80%, 1-6 long-term results 
with AXFBG have varied from 10% to > 70% at 5 
years, ii'13'28'29 This variation has led to a perception 
of AXFBG as a "compromised" procedure with a 
limited clinical role} °,a° After the introduction of 
externally supported prostheses by Sauvage t al.31 in 
1978, however, patency rates of AXFBG have 
dramatically improved. Several papers, including a 
previously published series from our institution, have 
demonstrated patency rates after AXFBG that ap- 
proach those from the historic AOFBG series, ls18 
This contemporary trend justifies reevaluation ofthe 
roles of AXFBG and AOFBG in the treatment of 
aortoiliac occlusive disease. 
Despite numerous AXFBG and AOFBG series in 
the literature, no prospective, randomized series has 
compared both procedures. In retrospective com- 
parisons, Ray et al., 13 Bunt ,  2° and Schneider et al. 22 
found inferior patency rates with AXFBG, whereas 
Johnson et al. 19 and Mason et al.21 demonstrated 
excellent results with no significant difference in 
long-term patency rates. These series, however, all 
included small numbers of patients in both AXFBG 
and AOFBG groups, which makes valid comparison 
difficult. Also, externally supported grafts were only 
used in the report of Schneider et al.22 The present 
study, which compares a large concurrently per- 
formed series of AOFBG and externally supported 
AXFBG, shows no difference in long-term patency 
rates. The primary patency rate at 5 years was 74% for 
AXFBG and 80% for AOFBG (p = NS). 
Significant differences were found between pa- 
tient groups that underwent AOFBG and AXFBG. 
AXFBG was the preferred procedure for patients 
with increased operative risk. The patients who 
underwent AXFBG in our study were on average a
decade older and a greater number had heart disease, 
renal failure, and previous intraabdominal or aortic 
surgery than those who underwent AOFBG. In the 
past, most AOFBG series have also included a large 
proportion of patients with claudication, ranging 
from 40% in Malone et al) to 76% in Crawford et al. s 
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Table VII, Life-table survival for aortofemoral bypass (n = 139) 
Period At  risk Death Withdrawn Interval survival Cummulative survival 
(too) (no.) (no.) (no.) rate rate SE 
0-1 139 1 3 0.99 0.99 0.01 
2-6 135 2 10 0.98 0.98 0.01 
7-I2 123 3 9 0.97 0.95 0.02 
13-24 111 9 27 0.91 0.86 0.03 
25-36 75 4 20 0.94 0.81 0.04 
37-48 51 2 10 0.96 0.78 0.05 
49-60 39 2 18 0.93 0.72 0.06 
In contrast, previously published series on AXFBG 
have varied widely in the severity of ischemic 
symptoms, ranging from 12% with claudication in 
Eugene t al. ~2 to 59% reported by Ray et al.la In the 
current study, only 20% of AXFBG were placed for 
claudication compared with 58% of AOFBG (p < 
0.001). Despite these major differences in patient 
populations, no difference was found in operative 
mortality, patency, or limb salvage rates between 
AOFBG and AXFBG groups. Patients who under- 
went AXFBG had fewer major complications, which 
perhaps reflects the operative procedure of decreased 
magnitude. 
The higher incidence of comorbid risk factors and 
the higher percentage of operations for limb salvage 
in patients who underwent AXFBG has been associ- 
ated with a shorter life expectancy than that found in 
patients who underwent AOFBG. The 5-year sur- 
vival rate after AXFBG has ranged from 26% 
reported by Eugene et al. I2 to 67% reported by 
Johnson et al.~9 In contrast, the 5-year survival rate 
for AOFBG has ranged from 59% reported by 
Szilagyi et al. 6 to 87% reported by Poulias et al. 32 
Survival of patients who required AOFBG has been 
estimated to be 10 years less than the "normal," 
nonatherosclerotic, age-adjusted male population, aa 
In this study, although the operative mortality rates 
did not differ, the long-term survival rates were 
significantly lower in patients who underwent 
AXFBG. Our reported 5-year survival rate of 45% 
after AXFBG and 72% after AOFBG is consistent 
with previously published reports. In the setting of 
this major difference in life expectancy, no difference 
is detectable in patency rates as calculated by life-table 
methods. 
It is not the purpose of this paper to suggest 
that AXFBG and AOFBG are equivalent proce- 
dures, a conclusion that could only result from a 
randomized trial. Rather, it seems reasonable to 
regard AXFBG as a useful treatment in a spectrum 
of options. These options include nonoperative 
treatment for patients with mild to moderate 
symptoms; percutaneous techniques for patients 
with minimal esions; AOFBG, which has excellent 
results when applied to good-risk patients; and 
AXFBG, which, when reserved for high-risk patients 
with limited life expectancy, produces equivalent 
results for patency and limb salvage. 
CONCLUSION 
Performance ofAXFBG in high-risk patients with 
aortoiliac occlusive disease is a safe practice that does 
not produce patency results inferior to those achieved 
with AOFBG. There appears to be no reason to avoid 
AXFBG in such patients because of concerns about 
patency or limb-salvage results. 
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DISCUSSION 
Dr. Frank W. LoGerfo (Boston, Mass.). Dr. Passman 
and his colleagues from Oregon have demonstrated com- 
mendable results in the modern treatment of aortoiliac 
occlusive disease and in their emphasis on the role of 
AXFBG. Without question, their patients who undergo the 
AXFBG procedure were at higher risk for death, as 
confirmed by age, previous cardiac disease, renal failure, 
and other factors. Furthermore, they were, by traditional 
measures, at higher risk for graft occlusion based on a 
higher incidence of limb salvage procedures, occlusion of 
the superficial femoral artery, and the need for simulta- 
neous distal bypass. 
On the basis of this experience, they raise a legitimate 
question. Should the indications for AXFBG be extended 
to include more patients who currently undergo AOFBG? 
In turn, I pose to them a question. If all of your patients 
had undergone AXFBG, what would have been achieved? 
At best, one death would have been eliminated. But 
because that patient died of a stroke, even that is unlikely. 
If all had undergone AXFBG, could you have really 
maintained a primary patency rate of > 80%, equivalent to 
AOFBG? Perhaps you can provide a different perspective 
on this matter, but as I see it, expanding the indications for 
AXFBG could be justified only if you had achieved a 0% 
mortality rate and a patency rate equivalent to AOFBG. I 
submit hat the simultaneous attainment ofthose two goals 
is sufficiently unlikely as to temper any enthusiasm that we 
abandon AOFBG as the gold standard. 
What fraction of patients who currently have aortoiliac 
occlusive disease should undergo AXFBG? At our hospital, 
of 313 aortoiliofemoral reconstructions over the past 4 
years, the breakdown was 60% AOFBG, 18% iliofemoral 
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bypass, 14% femorofemoral bypass, and only 8.7% 
AXFBG. The mortality rate for patients who underwent 
AOFBG was 1.1%. 
On the basis of the existing literature and our own 
experience, why should we not favor an alternative inter- 
pretation of your own data? Because your mortality rate for 
patients who underwent AOFBG is low and the patency is
well-established, why not extend your indications for 
AOFBG? This would avoid the concerns about disruption 
of the axillary anastomosis about which you have written: 
external pressure on the graft and the risk of warfarin anti- 
coagulation before or after graft thrombectomy. 
Dr. Passman and his colleagues have advanced the art 
of arterial reconstruction by .identifying and solving tech- 
nical problems associated with AXFBG. They have made it 
clear that this is an operation that vascular surgeons can 
turn to with confidence in the management of aortoiliac 
occlusive disease. 
Dr. Lloyd M. Taylor, Jr. Dr. LoGerfo asked why not 
perform only MX_FBG, and to be certain to cover both sides 
of the waterfront, he also asked why we should not do all 
AOFBG. It is important to understand that the purpose of 
this paper is not to suggest that either should be done to the 
exclusion of the other, but rather that AXFBG and AOFBG 
are techniques that produce quivalent results when applied 
appropriately to properly selected patients. It is not our 
intention to suggest that AXFBG should replace AOFBG, 
but rather that it can be selected with confidence in older, 
higher-risk patients without concern that in so doing the 
surgeon is condemning the patient to inferior patency 
results. 
Dr. Joseph R. Schneider (Evanston, Ill.). Your 
group's results with AXFBG are truly remarkable. I believe 
your success may be due in large measure to liberal selection 
criteria. As you know, we previously performed a similar 
analysis and found that AXFBG performed poorly as 
measured by patency rate when compared with AOFBG. I 
take issue with your statement that the concurrent com- 
parison of AXFBG and AOFBG is unknown-  at least three 
previous concurrent comparisons have been published. 
We were criticized by Dr. Willard Johnson for per- 
forming AXFBG in 25% of our patients. Your group 
performed AXFBG in nearly half of your patients. Our 
subsequent report noted that characteristics of patients 
who underwent AXFBG were dramatically different in 
reports from different institutions and that patency was 
highly dependent on indications and patient characteristics. 
We also pointed out that the inclusion of even a small 
number of patients with claudication may have a dramatic 
effect on patency calculations because these patients enjoy 
better patency, live longer, and thus have a disproportion- 
ate effect on the life-table patency calculations. Twenty 
percent of your patients had claudication, which is a 
relatively high number when compared with most previous 
reports of KXFBG. Although your patients' average age 
was 68 years, several previous reports, including ours, have 
presented series of patients with mean ages of > 70 years. 
Finally, one half of your AXFBG patients urvived 5 
years, whereas only one third of ours survived even 3 years. 
I don't think we're operating on the same kind of patients. 
Why not perform the lower-risk AXFBG in a young 
patient with clandication who can expect prolonged 
patency? Even if we and others could achieve your 
phenomenal success in terms ofpatency, as Dr. Rutherford, 
we, and others have shown, AXFBG is a poor hemody- 
namic performer that achieves a predicted resting ankle- 
brachial index of less than 0.7 with completely normal 
outflow. 
Mthough AXFBG may augment perfusion enough to 
salvage the limb, it does not provide the hemodynamic 
normalization that AOFBG does, and it would likely 
provide incomplete relief of claudication even with normal 
OUt_flOW. 
Given your success, what criteria do you now use to 
choose AXFBG over AOFBG for chronic occlusive arterial 
disease? Have you compared AXFBG and AOFBG when 
restricted to patients with limb-threatening ischemia? Have 
you measured the hemodynamic results of AXFBG in your 
patients? Have you been forced to convert any AXFBG to 
AOFBG because of thrombosis or inadequate relief of 
symptoms? 
Dr. Taylor. As emphasized in the presentation, we had 
no fixed criteria for the choice of AXFBG versus AOFBG. 
The choice was individualized by the surgeons who cared 
for the patients. AXFBG was chosen in patients who were 
believed to be at higher operative risk with shorter 
anticipated survival times. 
Your question about patency results as a function of the 
indication for surgery is an important one. In this study, no 
difference in patency was found in AXFBG that were 
performed for claudication as compared with those per- 
formed for limb-salvage indications. But the numbers are 
small, and the power to detect adifference may not be very 
great. 
You asked whether we have hemodynamic data that 
compare the results of AXFBG with those of AOFBG. We 
do, but we have not compared them because the patients 
were not randomized. 
Finally, were any AXFBG converted to AOFBG for 
thrombosis? The answer is no. But as pointed out in the 
manuscript, we performed multiple conversions in the 
opposite direction. When AOFBG failed, the follow-up 
procedure frequently was AXFBG. 
Dr. G. Patrick Glagett (Dallas, Tex.). What anti- 
thrombotic therapy do you use and what do you rec- 
ommend? 
Dr Taylor. We use aspirin therapy in all our patients 
except hose who have an identified disorder of coagula- 
tion. MI of our patients are screened for hypercoagulable 
disorders, and if one is identified, he or she is treated with 
warfarin. 
Dr. John A. Man_nick (Boston, Mass.). I believe that 
in discussing these two operations we sometimes forget 
that the technique of performing the AXFBG is very 
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important if good long-term results are to be achieved. 
Many surgeons have focused on doing an adequate 
technical AOFBG and pay little attention to the technical 
details that the Oregon group has quickly outlined in their 
presentation. I commend them for the analysis of how to 
do the procedure correctly and emphasize the fact that 
putting the anastomosis far proximal on the axillary artery, 
so that when the patient moves the arm the anastomosis 
isn't disrupted, is very important. 
Secondly, a smooth curve for the graft with no 
intermediate incision that the graft can get hung up on is 
very important. Finally, that they allow the full flow rate to 
both limbs to go down the entire axillary limb all the way 
to the distal anastomosis, thereby doubling that flow rate 
for the axillary limb through its entire course, is also very 
important. I think that many surgeons who criticize this 
operation haven't learned how to do it correctly; the 
Oregon group obviously has. 
Dr. David C. Brewster (Boston, Mass.). I congratu- 
late the Portland group. As is their style and as they have 
often done in the past, they have presented us with some 
provocative material and conclusions. I have several points 
of concern or caution. 
First, as pointed out in the presentation, this is not a 
randomized study, so is it possible that the degree or 
pattern of proximal occlusive disease was not equivalent i n
these patients and that it allowed AXFBG to be performed 
in patients with higher perceived risk but actually more 
favorable proximal inflow patterns of disease? Perhaps their 
more advanced ischemic symptoms were caused by more 
extensive infrainguinal occlusive disease. 
Second, I think it is important to recognize that your 
results of 75% primary patency with AXFBG are really 
extraordinary. Although Sauvage's group has presented 
somewhat similar data, I think it contradicts much of the 
acquired experience reported over the last 3 decades about 
the primary patency rates of extraanatomic grafts such as 
AXFBG. Do you believe that this contradiction is due to 
the use of externally supported grafts, or do you have any 
other postulates why your results are so much better than 
other reported experiences? 
Dr. Taylor. You are correct hat it is not a randomized 
study. The pattern of occlusive disease may differ between 
the two groups. We emphasized in the presentation that 
patients who underwent AXFBG had more extensive 
occlusive disease, a higher incidence of limb-salvage 
indications, and lower aggregate ankle-brachial pressure 
indices. The intriguing theory that perhaps they didn't have 
very severe inflow disease was not examined by our study, 
but it certainly will be in the future. 
The second question is why these results are better than 
they have been in the past. It's tempting to attribute the 
improvement to the externally supported prosthesis, and 
the results from Seattle, which are comparable with our 
own, using externally supported Dacron, would lend 
credence to that idea. I can only tell you that the results of 
AXFBG performed at our institution in the past decade are 
markedly improved compared with those that had been 
previously experienced, and I suspect that Dr. Mannick has 
touched on the reason for that, which is that the technical 
details have been worked out. 
Dr. Enrico Aster (Brooklyn, N.Y.). Dr. Mannick 
commented that your excellent results can be attributed to 
the technique. I must tell you that all the techniques that 
you discuss have been previously published in a chapter in 
Haimovici's book by Frank Veith and I about the long 
proximal anastomosis, the redundancy of the proximal 
graft, and putting the graft on top of distal anastomosis on 
the femorofemoral graft. So all of this has been published 
before. 
Despite all these techniques, our results are basically 
55% to 60% patency at 5 years, so I would therefore submit 
to you that the reason for your better results is not 
necessarily the technique, but rather because you're oper- 
ating on more patients with claudication, and we have 
limited our cases to limb-salvage situations. 
